Vivity, world’s leading EDOF intraocular lens reaches one million milestone

New Delhi: Alcon, the global leader in eye care has announced that its AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.

Alcon is the global leader in IOL with every four seconds an eye is implanted with an Alcon IOL (as per company’s claim).

“We are proud to celebrate the one million Vivity eyes empowering cataract patients to see the world with high quality vision from distance to functional near—day and night,” said Amar Vyas, Country Head for Alcon India. “This milestone embodies our commitment to addressing the diverse vision needs of today’s patients—who desire less dependence on glasses post-surgery and with monofocal visual disturbance profile—with a game-changing option that expands the patient candidacy pool.”

Vivity uses Alcon’s proprietary wavefront-shaping X-WAVE^TM technology, an advanced optical principal that simultaneously stretches and shifts light without splitting it—balancing quality of vision and maximizing range of vision.^, This unique mechanism of action is not refractive, does not introduce spherical aberrations and has ultimately expanded PCIOL access to even more patients.

Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe. The Vivity Registry Study^, demonstrates high patient satisfaction among several patient cohorts, as the vast majority of patients (92%) report they are satisfied with their sight and three-quarters of patients report no difficulty with their sight for everyday activities. With Vivity, more than 91% of patients report no haloes, glares, or starbursts. Additionally, nearly 50% of patients no longer need glasses for near activities; this percentage increases to 66% for patients who received mini-monovision.

Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, South Korea, Spain, U.K. and U.S. Alcon offers a family of IOLs designed to meet the unique vision needs of patients, including Vivity and PanOptix^®—the most implanted PCIOLs worldwide—Monofocal and Toric options. PanOptix surpassed 1M implants in early 2022, and is the most implanted trifocal worldwide.^,